Ledger.Open graph →
SEC Form D · Amendment · filed October 10, 2019

BioEclipse Therapeutics, Inc

Offering
$11.8M
Sold
$10.1M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
SOUTH SAN FRANCISCO, CA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (23)

Mark Frohlich · South San Francisco, CADirectorGregory Schiffman · South San Francisco, CADirectorBenjamin Carter · South San Francisco, CAExecCatherine Sohn · South San Francisco, CADirectorStephen Thau · South San Francisco, CAExecBiao He · South San Francisco, CADirectorElona Baum · South San Francisco, CADirectorChristopher A. Day · BECKENHAM, United KingdomDirectorStacey-Ann A. Kirkconnell · GRAND CAYMAN, Cayman IslandsDirectorTomofumi Oda · SINGAPORE, U0DirectorLani Baker · Tucson, AZExecStanton B. Shafer · Tucson, AZExecChris A. Santana · New York, NYDirectorColin Siew · SINGAPORE, U0DirectorPamela Reilly Contag · South San Francisco, CAExec · DirectorMichael Augins · Scottsdale, AZDirectorRezwan Manji · Scottsdale, AZDirectorJohn Platts · Austin, TXDirectorRobert Habermeier · Austin, TXDirectorRobert J. Geary · Houston, TXDirectorChad M. Tappendorf · NEW YORK, NYExecJ. F. Funnell · FAIRFAX, CAExecPamela Reilly Contag · South San Francisco, CAExec · Director

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗